Renal nerve ablation for hypertensive patients with chronic kidney disease

Current Vascular Pharmacology

Volumn 12, Issue 1, 2014, Pages 47-54

  Papademetriou, V ^a   Doumas, M ^b,c   Anyfanti, P ^c   Faselis, C ^b   Kokkinos, P ^a,b   Tsioufis, C ^a,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Chronic kidney disease; End stage renal disease; Hypertension; Mild renal insufficiency; Renal nerve ablation; Renal sympathetic denervation; Resistant hypertension; Sympathetic nervous system

Indexed keywords

CATECHOLAMINE;

ABLATION THERAPY; ACUTE HEART INFARCTION; ADRENERGIC SYSTEM; ALPORT SYNDROME; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; HUMAN; HYPERTENSION; KIDNEY DENERVATION; KIDNEY ISCHEMIA; PROTEINURIA; RENAL NERVE ABLATION; RISK FACTOR; SYMPATHECTOMY;

BLOOD PRESSURE; CATHETER ABLATION; HUMANS; HYPERTENSION; KIDNEY; RENAL INSUFFICIENCY, CHRONIC; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM;

EID: 84897418014     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113119990143     Document Type: Article

References (92)

1. Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation in hypertension. Curr Opin Nephrol Hypertens 2011; 20: 647-53.
2. Doumas M, Papademetriou V, Douma S, et al. Benefits from treatment and control of patients with resistant hypertension. Int J Hypertens 2010; 2011: 318549.
3. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-47.
4. US Renal Data Systems. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007.
5. Gilbertson DT, Liu J, Xue JL, et al. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 2005; 16: 3736-41.
6. United States Renal Data System. USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2008.
7. Centers for Disease Control and Prevention (CDC). Hospitalization discharge diagnoses for kidney disease: United States, 1980-2005. MMWR Morb Mortal Wkly Rep 2008; 57: 309-12.
8. Albright A, Burrows NR, Jordan R, Williams DE. The Kidney Disease Initiative and the Division of Diabetes Translation at the Centers for Disease Control and Prevention. Am J Kidney Dis 2009; 53: S121-S125.
9. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119.
10. Centers for Disease Control and Prevention (CDC). Racial differences in trends of end-stage renal disease, by primary diagnosis: United States, 1994-2004. MMWR Morb Mortal Wkly Rep 2007; 56: 253-56.
11. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701.
12. Beddhu S, Allen-Brady K, Cheung AK, et al. Impact of renal failure on the risk of myocardial infarction and death. Kidney Int 2002; 62: 1776-83.
13. Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003; 63: 1121-29.
14. Vincenti F, Amend WJ, Abele Feduska NJ, Salvatierra O Jr. The role of hypertension in hemodialysis-associated atherosclerosis. Am J Med 1980; 68: 363-9.
15. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic uremia. J Am Soc Nephrol 1999; 10: 1606-15.
16. Wilcox CS. Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables. Hypertension 2012; 59: 375-81.
17. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker of increased risk of stroke. Stroke 1997; 28: 557-63.
18. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-36.
19. Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol 2006; 47: 1-8.
20. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N; European Uremic Toxin Work Group. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-56.
21. Mann JF. Cardiovascular risk in patients with mild renal insufficiency: implications for use of ACE-inhibitors. Presse Med 2005; 34: 1303-8.
22. Mann JF, Gerstein HC, Pogue J, Lonn E, Yusuf S. Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE-inhibitors. Am J Cardiovasc Drugs 2002; 2: 157-62.
23. Mann JF, Gerstein HC, Dulau-Florea I, Lonn E. Cardiovascular risk in patients with mild renal insufficiency. Kidney Int 2003; 84: S192-S196.
24. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41: IIV, S1-91.
25. Weiner DE, Tabatabai S, Tighiouart H, et al. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis 2006; 48: 392-401.
26. Dalrymple LS, Katz R, Kestenbaum B, et al. Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med 2011; 26: 379-85.
27. National Institutes of Health. USRDS 2000 Annual Data Report. Bethesda, Md: National Institutes of Health; 2000. Publication No. (NIH) 00-3176: pp 589-684 and 69-75.
28. U.S. Renal Data System, USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007.
29. Herzog CA, Mangrum JM, Passman R. Sudden cardiac death and dialysis patients. Semin Dial 2008; 21: 300-7.
30. Raine AEG, Schwarz U, Ritz E. The patient with uremia: hypertension and cardiac problems. In: Oxford Textbook of Clinical Nephrology, ed. By Davison AM et al., Oxford University Press, 1998; p. 1885-919.
31. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119.
32. Gupta R, Birnbaum Y, Uretsky BF. The renal patient with coronary artery disease: current concepts and dilemmas. J Am Coll Cardiol 2004; 44: 1343-53.
33. Herzog CA, Ma JZ, Collins AJ. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 2002; 106: 2207-11.
34. Szczech LA, Reddan DN, Owen WF, et al. Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int 2001; 60: 292-99.
35. Manske CL, Wang Y, Rector T, Wilson RF, White CW. Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure. Lancet 1992; 340: 998-1002.
36. Ishio N, Kobayashi Y, Takebayashi H, et al. Impact of drug-eluting stents on clinical and angiographic outcomes in dialysis patients. Circ J 2007; 71: 1525-9.
37. Nakazawa G, Tanabe K, Aoki J, et al. Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents. Catheter Cardiovasc Interv 2007; 69: 808-14.
38. Izzo JL and Campese VM. "Hypertension and renal disease, " in The Kindy, B. M. Brenner and F. C. Rector's, Eds., Elsevier, New York, NY, USA, 7th edition, 2004.
39. Galla JH. "Hypertension in renal parenchymal disease, " in The Kidney, B. M. Brenner, Ed., pp. 2035-2058, W. B. Saunders, Philadelphia, Pa, USA, 2000.
40. Muntner P, Anderson A, Charleston J, et al. Hypertension awareness, treatment and control in adults with CKD: results from the chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis 2010; 55: 441-51.
41. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC and Barre PE. "Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease, " Kidney International, vol. 49, no. 5, pp. 1379-1385, 1996.
42. Agarwal R. Blood pressure goal in chronic kidney disease: what is the evidence? Curr Opin Nephrol Hypertens 2011; 20: 229-32.
43. Faselis C, Doumas M, Papademetriou V. Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens 2011; 2011: 236239.
44. Schalekamp MA, Manin't Veld AJ, Wenting GJ. The second Sir George Pickering memorial lecture. What regulates whole body autoregulation? Clinical observations. J Hypertens 1985; 3: 97-108.
45. Wilcox CS, Aminoff MJ, Slater JD. Sodium homeostasis in patients with autonomic failure. Clin Sci Mol Med 1977; 53: 321-8.
46. Cuche JL, Prinseau J, Selz F. Plasma free, sulfo and glucuroconjugated catecholamines in uremic patients. Kidney Int 1986; 30: 566-572.
47. Koomans HA, Geers AB, Boer P, Dorhout Mees EJ. Plasma volumes, noradrenaline levels and renin activity during posture changes in end-stage renal failure. Clin Physiol 1984; 4: 103-15.
48. McGrath BP, Tiller DJ, Bune A, Chalmers JP, Korner PI, Uther JB. Autonomic blockade and the Valsalva maneuver in patients on maintenance hemodialysis: A hemodynamic study. Kidney Int 1977; 12: 294-302.
49. Levitan D, Massry SG, Romoff M, Campese VM. Plasma catecholamines and autonomic nervous system function in patients with early renal insufficiency and hypertension: Effect of clonidine. Nephron 1984; 36: 24-9.
50. Schohn D, Weidmann P, Jahn H, Beretta-Piccoli C. Norepinephrine-related mechanism in hypertension accompanying renal failure. Kidney Int 1985; 28: 814-22.
51. DiBona GF. Neural control of renal function in health and disease. Clin Auton Res 1994; 4: 69-74.
52. Converse RL Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-18.
53. Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106: 1974-79.
54. Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003; 14: 3239-3244.
55. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001; 12: 2427-33.
56. Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-8.
57. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34: 724-8.
58. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-9.
59. Penne EL, Neumann J, Klein IH, et al. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. J Nephrol 2009; 22: 208-15.
60. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: Is the podocyte the culprit? Kidney Int 54: 687-697, 1998.
61. Zhang H, Faber JE. Trophic effect of norepinephrine on arterial intima-media and adventitia is augmented by injury and mediated by different β1-adrenoceptor subtypes. Circ Res 2001; 89: 815-22.
62. Erami C, Zhang H, Ho JG, French DM, Faber JE. Alpha(1)-adrenoceptor stimulation directly induces growth of vascular wall in vivo. Am J Physiol Heart Circ Physiol 2002; 283: H1577-H1587.
63. Elenkov IJ, Chrousos GP. Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann N Y Acad Sci 2002; 966: 290-303.
64. Vaziri ND. Effect of chronic renal failure on nitric oxide metabolism. Am J Kidney Dis 2001; 38: S74-S79.
65. Matsuoka H, Nishida H, Nomura G, Van Vliet BN, Toshima H. Hypertension induced by nitric oxide synthesis inhibition is renal nerve dependent. Hypertension 1994; 23: 971-5.
66. Aizawa T, Ishizaka N, Taguchi J, et al. Heme-oxygenase-1 is upregulated in the kidney of angiotensin II-induced hypertensive rats: Possible role in renoprotection. Hypertension 2000; 35: 800-6.
67. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke 1997; 28: 557-63.
68. Rinkel GJ. Intracranial aneurysm screening: indications and advice for practice. Lancet Neurol 2005; 4: 122-8.
69. Tsioufis C, Kokkinos P, Macmanus C, et al. Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular risk. J Hypertens 2010; 28: 2299-308.
70. Amin JK, Xiao L, Pimental DR, et al. Reactive oxygen species mediate alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J Mol Cell Cardiol 2001; 33: 131-9.
71. Zoccali C, Mallamaci F, Tripepi G, et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 2002; 40: 41-6.
72. Kurata C, Uehara A, Sugi T, et al. Cardiac autonomic neuropathy in patients with chronic renal failure on hemodialysis. Nephron 2000; 84: 312-9.
73. Miyanaga H, Yoneyama S, Kamitani T, Kawasaki S, Takahashi T, Kunishige H. Abnormal myocardial uptake and clearance of 123Ilabeled metaiodobenzylguanidine in patients with chronic renal failure and autonomic dysfunction. J Nucl Cardiol 1996; 3: 508-15.
74. Vita G, Messina C, Savica V, Bellinghieri G. Uraemic autonomic neuropathy. J Auton Nerv Syst 1990; 30 [Suppl]: S179-S184.
75. Barajas L, Liu L, Powers K. Anatomy of the renal innervation: Intrarenal aspects and ganglia of origin. Can J Physiol Pharmacol 1992; 70: 735-49.
76. Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev 1991; 71: 659-82.
77. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77: 75-197.
78. Bigazzi R, Kogosov E, Campese VM. Altered norepinephrine turnover in the brain of rats with chronic renal failure. J Am Soc Nephrol 1994; 4: 1901-7.
79. Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis 1995; 26: 861-5.
80. Greenwood B. The origins of sympathectomy. Med Hist 1967; 11: 165-9.
81. Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation and systemic hypertension. Am J Cardiol 2010; 105: 570-6.
82. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension: results in 1,266 cases. J Am Med Assoc 1953; 152: 1501-4.
83. Krum H, Schlaich M, Whitburn R, et al. Carheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-81.
84. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-7.
85. Petidis K, Anyfanti P, Doumas M. Renal sympathetic denervation: renal function concerns. Hypertension 2011; 58: e19; author reply e20.
86. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-9.
87. Schlaich M. A Novel Catheter Based Approach to Denervate the Human Kidney Reduces Blood Pressure and Muscle Sympathetic Nerve Activity in a Patient with End Stage Renal Disease and Hypertension. European Society of Hypertension Meeting June 2009.
88. Prochnau D, Lauten A, Busch M, Kuehnert H, Figulla HR, Surber R. Catheter-based radiofrequency ablation therapy of the renal sympathetic-nerve system for drug resistant hypertension in a patient with end-stage renal disease. Int J Cardiol 2012; 154: e29-30.
89. Hering D, Mahmoud F, Walton AS, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012; doi: 10.1681/ASN.2011111062.
90. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123: 1940-6.
91. Doumas M, Anyfanti P, Bakris G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens 2012; 30: 874-6.
92. Papademetriou V, Doumas M, Tsioufis K. Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension. Int J Hypertens 2011; 2011: 196518.